Clinical validation of a bioMARKer for use in INtestinal PATHologies

Información del proyecto

MARKinPATH

Identificador del acuerdo de subvención: 651065

DOI 10.3030/651065

Proyecto cerrado

Fecha de la firma de la CE 8 Septiembre 2014

Fecha de inicio 1 Octubre 2014

Fecha de finalización 28 Febrero 2015

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total € 71 429,00

Aportación de la UE € 50 000,00

Coordinado por

VENTER PHARMA S.L.
Spain

Objetivo

MARKinPATH global innovation project aims at undertake the clinical validation of Xylose, after ingestion of Gaxilose, as a Biomarker of intestinal diseases. Currently, the measurement of Xylose after ingestion of Gaxilose is used to evaluate hypolactasia in adults. MARKinPATH is focused to improve the hypolactasia diagnosis; broaden the pathologies to monitor and to extend his use to paediatrics population.

MARKinPATH will meet the demand of the EU on and innovation in healthcare, by enhancing diagnosis and management of intestinal pathologies. The resulting solution will also contribute to cost-effective and efficient health expenditure.
Xylose-based, after ingestion of Gaxilose, biomarker improves technical features such as specificity and sensitivity with respect to the other tests available in regular clinical practice. Furthermore, alternative methods such as Hydrogen breath test (HBT) and the Lactose tolerance test (LTT) are invasive and have adverse effects that can be very annoying for the patient.

Venter Pharma is a highly innovative SME with more than 11 years focused on advanced research, development and commercialization of clinical solutions in this field. Venter Pharma has a relevant Intellectual Capital and an extensive background in these technologies.

MARKinPATH would suppose a massive-but-necessary growth and the consolidation of Venter Pharma in the pharmaceutical market.

Ámbito científico

• medical and health sciences › clinical medicine › gastroenterology › inflammatory bowel disease
• medical and health sciences › basic medicine › immunology › autoimmune diseases
• medical and health sciences › health sciences › nutrition
• medical and health sciences › basic medicine › pathology
• medical and health sciences › clinical medicine › paediatrics

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Tema(s)

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Convocatoria de propuestas

H2020-SMEInst-2014-2015

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEINST-1-2014

Régimen de financiación

SME-1 - SME instrument phase 1

Coordinador

VENTER PHARMA S.L.

• Aportación neta de la UEn: € 50 000,00
• Dirección: CALLE AZALEA 1 ; 28109 ALCOBENDAS ; España
• Pyme Organización definida por ella misma como pequeña y mediana empresa (pyme) en el momento de la firma del acuerdo de subvención. Sí:
  Región
  Comunidad de Madrid › Comunidad de Madrid › Madrid
• Región: Comunidad de Madrid › Comunidad de Madrid › Madrid
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00